ISPOR Bernie O'Brien New Investigator Award
Anthony Newall, PhD, MPH, BSc, Associate Professor, UNSW Australia, School of Public Health and Community Medicine, The University of New South Wales, Sydney, NSW Australia
The ISPOR Bernie O'Brien New Investigator Award was established in 2004 to honor the long-standing commitment of Bernie J. O'Brien, PhD to training and mentoring new scientists in the fields of outcomes research and pharmacoeconomics.
The recipient of the ISPOR Bernie O'Brien New Investigator Award is selected by the O'Brien New Investigator Award Committee. The recipient shall be a member of ISPOR on the date of nomination and be nominated by an individual who has been an ISPOR member in good standing for at least two consecutive years prior to the date of nomination. Evidence of exceptional promise shall be assessed by evaluating the nominee's emerging body of technical and scholarly work in the fields of pharmacoeconomics and outcomes research. The emerging body of work may include research publications, technical reports and papers, books and book chapters, and other scholarly activities that establish the importance of the nominee's early contributions. The nominees shall be no more than 7 years from the receipt of their last degree in outcomes research or related field and no more than 10 years from their first publication in outcomes research or related field.
A candidate may only be nominated for one major ISPOR award in a year.
A call for nominations from the membership and the award selection criteria will be are published in November-December Value & Outcomes Spotlight. The New Investigator Committee Core Group meets via teleconference in March to discuss each of the nominees and select the nominee who best meets the criteria. The nominee is then forwarded to the Board of Directors for final approval.
Nature of the Award:
The Award will be known as "ISPOR Bernie J. O'Brien New Investigator Award."
The Award will be presented at the ISPOR Annual International Meeting or the Annual European Congress each year.
The Award consists of a plaque, complimentary meeting registration, an unrestricted research grant of US$5,000.00 and up to US$1,500.00 for travel expenses.
Timeline & Procedures: Following is the selection process timeline:
» A Call for Nominations is published in Value & Outcomes Spotlight, December 15 issue.
» An email message is sent to all Award Committee members requesting nominees who have advanced in the field.
» A second email message is sent to all ISPOR membership reminding them of the February 15 deadline for the nominations
» The New Investigator Award Committee Core Group meets via teleconference to discuss and evaluate nominations.
Nominations for the Bernie J. O'Brien New Investigator Award require a letter of support for the nominee and a current edition of the nominee's CV, and should be sent to: firstname.lastname@example.org.
Sherri Rose, PhD
Associate Professor, Department of Health Care Policy
Harvard Medical School
Boston, MA, USA
Sherri Rose, PhD, is an associate professor in the Department of Health Care Policy at Harvard Medical School, where her work is centered on developing and integrating innovative statistical approaches to advance human health. Broadly, Dr. Rose's methodological research focus is nonparametric machine learning for causal inference and prediction. Within health policy, Dr. Rose works on risk adjustment, comparative effectiveness research, and health program impact evaluation. She also co-leads the Health Policy Data Science Lab at Harvard where she directs projects in computational health economics and clinical informatics. Dr. Rose coauthored the first book on machine learning for causal inference, and her recent honors include an NIH Director's New Innovator Award to develop robust estimators for generalizability. Her research has been featured in The New York Times, USA Today, Slate, and The Boston Globe. Dr. Rose received her PhD in Biostatistics from UC Berkeley before completing an NSF Mathematical Sciences Postdoctoral Research Fellowship at Johns Hopkins University.
James D. Chambers, PhD, MPharm, MSc
Assistant Professor, Tufts Medical Center
Boston, MA, USA
James D. Chambers, PhD, MPharm, MSc, is an investigator at the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and an assistant professor of medicine at Tufts University in Boston, MA. James received his MPharm degree from Queens University in Belfast and previously worked as a pharmacist in the UK and Ireland. He also obtained an MSc from the University of York and PhD from Brunel University. James' research interests include examining the factors that influence coverage policy for medical technology, pharmaceutical innovation, and the use and potential value of cost-effectiveness analysis in the US health care system.
Anthony Newall, PhD
Dr. Newall is an Associate Professor in Health Economics at The School of Public Health and Community Medicine, UNSW Australia. He is also an Honorary Fellow at the Australian National Centre for Immunisation Research and Surveillance. He completed his MPH (Hons) and PhD at the University of Sydney on the cost-effectiveness of vaccination programs.
His main research area is the economic evaluation of infectious disease prevention strategies, as well as the statistical and epidemiological analyses that inform these evaluations. He has over 40 peer-reviewed publications on a range of vaccine preventable diseases, including the epidemiology and cost-effectiveness of prevention strategies for influenza (seasonal and pandemic), pneumococcal disease, rotavirus, and human papillomavirus.
He has been appointed to the World Health Organization Roster of Experts in the area of Health Economics and has been a visiting scholar at the National Institutes of Health. He has received several awards for his research and public health impact, including the prestigious Aileen Plant Memorial Prize and the Dean's Rising Star Award from the Faculty of Medicine, UNSW.
Anupam B. Jena, MD, PhD
Assistant Professor, Harvard Health Care Policy, Harvard Medical School, Boston, MA, USA
Dr. Jena is an Assistant Professor of health care policy and medicine at Harvard Medical School and an internist at Massachusetts General Hospital. Dr. Jena is also a Faculty Research Fellow at the National Bureau of Economic Research. Dr. Jena's research involves several areas of health economics and policy including the economics of medical innovation and cost-effectiveness, the economics of physician behavior, medical malpractice, and productivity in health care. Dr. Jena graduated Phi Beta Kappa from the Massachusetts Institute of Technology and received his MD and PhD in Economics from the University of Chicago. He completed his residency in internal medicine at Massachusetts General Hospital. He is a recipient of the 2007 Eugene Garfield award from Research America for the best paper on the economic impact of medical technology. In 2013, he was the recipient of the NIH Director's Early Independence Award, a 5-year award given to 10-15 junior scientists nationally who show exceptional promise to conduct cross-cutting biomedical and behavioral science research.
Josh J. Carlson, MPH, PhD
Dr. Carlson is an Assistant Professor in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington and an affiliate faculty member at the Fred Hutchinson Cancer Research Center. He graduated with his PhD from the Institute for Public Health Genetics in the School of Public Health and Community Medicine at the University of Washington in 2007 and conducted his postdoctoral training in pharmacoeconomics at the University of Washington from 2007-2009. Dr. Carlson's current research interests and work to date has primarily focused on the intersection of three areas: 1) genomics and emerging technologies in the field of personalized medicine, 2) uncertainty both in our decision-making processes and as the concept applies to the application of medical technologies in "real world" settings (i.e. outside of clinical trials) including comparative effectiveness research, and 3) economic and policy options to address these uncertainties as we seek to improve our healthcare system and the health of our population.
Jennifer M. Polinski, ScD, MPH, MS (MPH, Health Education, Emory University; MS and ScD, Epidemiology, Harvard School of Public Health) is an epidemiologist and health services researcher in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston, MA. She holds faculty appointments at Harvard Medical School and Harvard School of Public Health, where she teaches a course in epidemiologic methods applied to health services research. Dr. Polinski’s research interests focus on the management and treatment of chronic disease, patient and physician education, and the impact of health interventions and health policy changes on elderly populations. She has a special interest in government-funded health care programs. Her recent work examined changes in Medicare beneficiaries’ drug utilization and health outcomes following the inception of the Medicare Part D program. Current projects include identifying predictors of type 2 diabetes treatment progression, developing tools to improve primary medication adherence, and studying methods for causal inference in comparative effectiveness studies.
Joanne LaFleur, PharmD, MSPH, is Assistant Professor in the Department of Pharmacotherapy within the University of Utah College of pharmacy. She has a joint appointment as a researcher in the Salt Lake City Veterans Affairs Informatics, Decision Enhancement, and Surveillance (IDEAS) center, where she focuses on applying the tools of health economics, biomedical informatics, and pharmacoepidemiology to outcomes research. She received her PharmD degree from the University of Utah in 2003 and went on to complete a Fellowship in Pharmacoeconomics and Outcomes Research and a Master’s degree in Public Health in 2005, both at the University of Utah. She spent 4 years as faculty on the research track, and recently changed tracks to join the tenure track faculty. The focus of her CDA, entitled “Knowledge engineering for decision support in osteoporosis,” is on the development of clinical decision support tools for osteoporotic fracture prevention.